Lead Product(s) : Vidutolimod
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Compassionate Use of Vidutolimod
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Vidutolimod
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001 (vidutolimod), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001, an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger body’s innate immune system to attack tumors in combination ...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
Details : The acquisition strengthens Regeneron's portfolio of immuno-oncology candidates, by acquiring Checkmate's pipeline including lead candidate, CMP-001 (vidutolimod), an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 agonist delivered i...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $250.0 million
May 31, 2022
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Iowa Holden Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of this study is to determine the dose of CMP-001 (vidutolimod) that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity in patients with relapsed lymphoma who have failed at least one line of therapy.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Iowa Holden Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Details : Regeneron's resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $250.0 million
April 19, 2022
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Vidutolimod,Cemiplimab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Checkmate Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Checkmate announced development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”).
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 05, 2021
Lead Product(s) : Vidutolimod,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Checkmate Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : XOMA
Deal Size : $32.0 million
Deal Type : Acquisition
Details : Vidutolimod triggers the body’s innate immune system to attack tumors in combination with other therapies. XOMA has acquired all future potential royalties from commercial sales of vidutolimod, which are tiered from high-single to double digits.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : XOMA
Deal Size : $32.0 million
Deal Type : Acquisition
Lead Product(s) : Vidutolimod
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 07, 2021
Lead Product(s) : Vidutolimod
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Vidutolimod
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable